Shares of Mobileye Global Inc. (NASDAQMBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded down 0.52% to 37,518.35 while the NASDAQ fell 0.98% to 14,621.38. The S&P 500 also fell, dropping, 0.61% to 4,713.82.
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 150 points on Wednesday. The Dow traded down 0.79% to 37,417.28 while the NASDAQ fell 1.01% to 14,616.58. The S&P 500 also fell, dropping, 0.78% to 4,705.94.
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.35% to 37,584.32 while the NASDAQ fell 0.66% to 14,668.39. The S&P 500 also fell, dropping, 0.49% to 4,719.52.
Nemaura Medical (NASDAQNMRD), a developer of a daily-wear, noninvasive glucose sensor and digital healthcare programs, is reporting on decisions that will impact its listing status on the NASDAQ Capital Market; the company also released key information regarding its broader strategic direction. According to the announcement, the company’s management team and medical board of directors has carefully evaluated NASDAQ’s action to delist Nemaura Medical and will accept that decision and move to the OTC markets. The company noted that several factors were considered in reaching this decision, including challenges outside of the company’s control that have led to a significant attrition of company share price. The announcement also noted that Nemaura is actively pursuing strategic partnerships critical to driving Nemaura Medical’s growth and creating shareholder value. The company noted that it will provide regular updates on any progress, strategic partnerships and material developments impacting shareholders and will continue to file reports with the U.S. Securities & Exchange Commission.
Nemaura (NASDAQNMRD), developer of a daily wear non-invasive glucose sensor and digital health care programs, today announced that the Nasdaq Hearings Panel granted the company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1, 2024, to evidence compliance with all applicable criteria for continued listing on the Nasdaq Capital Market. Nemaura intends to continue with its commercial endeavors while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearings Panel’s decision.
Nemaura (NASDAQNMRD), developer of a daily wear non-invasive glucose sensor and digital health care programs, today announced the execution of a strategic agreement for a $10 million credit facility, which is expected to support the company’s strategic growth plans. Nemaura recognizes the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, and has proactively pursued a funding strategy that minimizes dilution, which the Company believes aligns with the best interests of its valued shareholders. The $10 million credit facility, structured to be non-dilutive, empowers Nemaura to draw down a maximum of $1 million per month, providing a steady and controlled infusion of capital to support its commercialization initiatives.
Nemaura Medical (NASDAQNMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, is reporting on its financial and business results for the quarter ended Sept. 30, 2023, and providing a business update. Corporate highlights of the report show continued support of its United Kingdom licensee, including efforts to obtain reimbursement for sensors in the area; advanced development of the BEAT diabetes offering; development of NMRD’s consumer metabolic health platform, including possible deployment as a bolt-on service into existing metabolic and wellness programs or to support a direct-to-consumer offering; approval from the Saudi Arabia Food and Drug Agency for marketing of sugarBEAT in the Kingdom of Saudi Arabia (KSA); and continued trials of the company’s prediabetes and consumer metabolic health program with the UK National Health Service. Financial highlights include R&D expenses of $491,803 and $257,061 for the three months ended Sept. 30, 2023 and 2022, respectively; general and administrative expenses totaling $1,558,742 and $1,369,155 for same two periods; net loss coming in at $1,203,454 and $3,855,700 for the three months ended Sept. 30, 2023 and 2022, respectively; and cash and cash equivalents totaling approximately $4.4 million.
NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 15-16, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Nemaura Medical (NASDAQNMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, has appointed artificial intelligence (“AI”) specialist Nikolai Rozanov as strategic adviser in the company’s AI development. According to the announcement, Rozanov will assist in development of Nemaura’s AI health coach and strengthen outcomes in its CGM-based metabolic and type 2 diabetes programs. Rozanov has been recognized by Forbes magazine in its prestigious “30 Under 30” ranking. His appointment solidifies Nemaura’s expertise in the growing AI sector at a time when AI developments in healthcare are gathering pace and put the company in an ideal position to further integrate data from its CGM to create tailored programs that can make tailored personalized recommendations. “We are excited to be working with Nikolai to leverage our CGM data to give better insights to members,” said Nemaura Medical CEO Dr. Faz Chowdhury in the press release. “The use of AI-based models is becoming more widespread, and we believe they have a vital role to play in the healthcare and lifestyle sector. Deeper personalized insights better engage users, and the capability of AI means this can be scaled efficiently.”
Nemaura (NASDAQNMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that its CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I. virtual conference. Dr. Chowdhury’s presentation is scheduled to begin at 11 a.m. ET on Sept. 27, 2023. Interested parties should visit https://ibn.fm/nJxPW to register for the event.
